Why the study?
The ischaemia/bleeding trade-off during anti-platelet therapy may differ between East Asians and non-East Asians.
Does prolonged DAPT affect the ischaemia/bleeding risk trade-off differently in East Asians compared to non-East Asians?
Does prolonged DAPT affect the ischaemia/bleeding risk trade-off differently in East Asians compared to non-East Asians?
Prolonged DAPT in East Asians may not reduce ischaemic risk but significantly increases bleeding risk, highlighting important racial differences in anti-platelet therapy trade-offs.
Caution advised with prolonged DAPT in East Asians due to bleeding without ischaemic benefit; challenges uniform guidelines and extends ethnic-specific evidence.
We suggest that the ischaemia/bleeding trade-off may be different between East Asians and non-East Asians. In East Asians, prolonged DAPT may have no effect in reducing the ischaemic risk, while significantly increases the bleeding risk.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: